← 返回

结外 NK/T 细胞淋巴瘤:当前方法与未来方向

英文原题:Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions.

查看英文原题

Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions.

PubMed 2022/05/10(内容时间) J Clin Med Q1 · IF 3.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

结外自然杀伤/T(NK/T)细胞淋巴瘤(ENKTL)是一种罕见的非霍奇金淋巴瘤亚型,通常表现为孤立的鼻腔肿块,但相当一部分患者表现为晚期疾病,预后显著较差。局限期疾病的标准治疗为化疗和放疗,而晚期疾病患者则接受含L-天冬酰胺酶的化疗方案。现代放疗技术的加入以及将L-天冬酰胺酶纳入化疗方案,已显著改善了该疾病的疗效,但复发和因复发导致的死亡仍然常见。鉴于高复发率,已有多种新疗法被评估用于该疾病的治疗。在本综述中,我们探讨了ENKTL的当前标准治疗,以及已被评估用于其治疗的新疗法和这些疗法背后的生物学认识。

展开英文摘要原文

Extranodal natural killer/T(NK/T)-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma that typically presents with an isolated nasal mass, but a sizeable minority present with advanced stage disease and have a significantly poorer prognosis. Those with limited disease are standardly treated with chemotherapy and radiation while those with advanced stage disease are treated with L-asparaginase containing chemotherapy regimens.

The addition of modern radiation therapy techniques and the incorporation of L-asparaginase into chemotherapy regimens have significantly improved outcomes in this disease, but relapses and death from relapsed disease remain frequent. Given the high rate of relapse, several novel therapies have been evaluated for the treatment of this disease. In this review, we explore the current standard of care for ENKTL as well as novel therapies that have been evaluated for its treatment and the biologic understanding behind these therapies.

论文信息

作者
Reneau JC、Shindiapina P、Braunstein Z、Youssef Y、Ruiz M、Farid S、Hanel W、Brammer JE
单位
Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.United States
文献类型
综述
期刊
Journal of clinical medicine2022 May 10
原文标识
PubMed 35628826 · DOI 10.3390/jcm11102699